Aliases & Classifications for Cerebellar Disease

MalaCards integrated aliases for Cerebellar Disease:

Name: Cerebellar Disease 12 14
Cerebellar Diseases 41 69
Cerebellar Dysfunction 51
Cerebellar Disorders 40

Classifications:



External Ids:

Disease Ontology 12 DOID:2786
MeSH 41 D002526
UMLS 69 C0007760

Summaries for Cerebellar Disease

MedlinePlus : 40 When you play the piano or hit a tennis ball you are activating the cerebellum. The cerebellum is the area of the brain that controls coordination and balance. Problems with the cerebellum include Cancer Genetic disorders Ataxias - failure of muscle control in the arms and legs that result in movement disorders Degeneration - disorders caused by brain cells decreasing in size or wasting away Treatment of cerebellar disorders depends on the cause. In some cases, there is no cure but treatment may help with symptoms. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Cerebellar Disease, also known as cerebellar diseases, is related to spinocerebellar ataxia 2 and spinocerebellar ataxia 1, and has symptoms including cerebellar ataxia/dyskinesia, sleeplessness and vertigo/dizziness. An important gene associated with Cerebellar Disease is CACNA1A (Calcium Voltage-Gated Channel Subunit Alpha1 A), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Myometrial Relaxation and Contraction Pathways. The drugs Clonidine and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include cerebellum, brain and liver, and related phenotype is behavior/neurological.

Related Diseases for Cerebellar Disease

Diseases related to Cerebellar Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Related Disease Score Top Affiliating Genes
1 spinocerebellar ataxia 2 31.2 ATXN3 ATXN7 CACNA1A
2 spinocerebellar ataxia 1 31.2 ATXN3 ATXN7 CACNA1A
3 machado-joseph disease 31.1 ATXN3 ATXN7 CACNA1A
4 spinocerebellar ataxia, autosomal recessive 1 30.8 APTX SACS SETX
5 autosomal dominant cerebellar ataxia 27.0 ATXN10 ATXN3 ATXN7 CACNA1A ITPR1 LOC108660406
6 aceruloplasminemia 23.7 APTX ATM ATP1A3 ATP2B3 ATXN10 ATXN3
7 cerebellar ataxia, mental retardation, and dysequilibrium syndrome 1 11.4
8 leukodystrophy, demyelinating, adult-onset, autosomal dominant 11.0
9 polyglucosan body neuropathy, adult form 10.9
10 cerebellar ataxia, cayman type 10.9
11 medulloblastoma 10.7
12 cowden syndrome 1 10.7
13 spinocerebellar ataxia 10 10.7
14 dandy-walker syndrome 10.6
15 mannosidosis, alpha b, lysosomal 10.5
16 spinocerebellar ataxia 6 10.3 ATXN3 ATXN7 CACNA1A
17 spinocerebellar ataxia 17 10.3 ATXN3 ATXN7 CACNA1A
18 ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia 10.1 APTX SACS SETX
19 spastic ataxia, charlevoix-saguenay type 10.1 APTX SACS SETX
20 vitamin e, familial isolated deficiency of 10.0 APTX SACS SETX
21 friedreich ataxia 1 10.0 APTX ATXN3 CACNA1A SETX
22 apraxia 10.0 APTX ATM SETX
23 spinocerebellar ataxia 18 9.9 ATXN3 ATXN7 CACNA1A PLEKHG4 SPTBN2
24 kearns-sayre syndrome 9.9 ATXN7 COQ8A SACS
25 hereditary ataxia 9.9 ATXN3 ATXN7 CACNA1A PPP2R2B
26 spinocerebellar ataxia 15 9.9 ITPR1 SPTBN2
27 spinocerebellar ataxia 12 9.9 ATXN3 ATXN7 CACNA1A PPP2R2B
28 dentatorubral-pallidoluysian atrophy 9.9 ATXN3 ATXN7 CACNA1A PPP2R2B
29 nervous system disease 9.9 ATM ATXN3 CACNA1A
30 autosomal recessive cerebellar ataxia 9.9 APTX ATM COQ8A SETX
31 tremor 9.8
32 spinocerebellar ataxia 31 9.7 ATXN3 ATXN7 CACNA1A PLEKHG4 SACS SETX
33 multiple sclerosis 9.6
34 stiff-person syndrome 9.6
35 ataxia and polyneuropathy, adult-onset 9.6
36 hyperekplexia 1 9.6
37 neuronitis 9.6
38 spinocerebellar ataxia 36 9.5 ATXN10 NOP56 PPP2R2B
39 spinocerebellar ataxia 7 9.4
40 cerebrotendinous xanthomatosis 9.4
41 xanthomatosis 9.4
42 langerhans cell histiocytosis 9.4
43 ataxia-oculomotor apraxia 3 9.4
44 aphasia 9.4
45 dementia 9.4
46 diarrhea 9.4
47 histiocytosis 9.4
48 cerebritis 9.4
49 polycythemia 9.4
50 speech disorder 9.4

Graphical network of the top 20 diseases related to Cerebellar Disease:



Diseases related to Cerebellar Disease

Symptoms & Phenotypes for Cerebellar Disease

UMLS symptoms related to Cerebellar Disease:


cerebellar ataxia/dyskinesia, sleeplessness, vertigo/dizziness, dysdiadochokinesis, adiadochokinesis, chronic pain, tremor, syncope, seizures, sciatica, pain, headache, cerebellar ataxia, back pain, ataxia

MGI Mouse Phenotypes related to Cerebellar Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.32 ATM ATP1A3 ATXN3 ATXN7 CACNA1A CALB1

Drugs & Therapeutics for Cerebellar Disease

Drugs for Cerebellar Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 189)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4 4205-90-7 2803
2
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
3
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
4
Metformin Approved Phase 4 657-24-9 4091 14219
5
Pioglitazone Approved, Investigational Phase 4,Phase 3 111025-46-8 4829
6
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
7
Citalopram Approved Phase 4 59729-33-8 2771
8
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
9
Amantadine Approved Phase 4 768-94-5 2130
10 Adrenergic Agents Phase 4
11 Adrenergic Agonists Phase 4
12 Adrenergic alpha-2 Receptor Agonists Phase 4
13 Adrenergic alpha-Agonists Phase 4
14 Analgesics Phase 4,Phase 1,Phase 2
15 Antihypertensive Agents Phase 4,Phase 2
16 Autonomic Agents Phase 4,Phase 3,Early Phase 1
17 Contraceptive Agents Phase 4
18 Estradiol 17 beta-cypionate Phase 4
19 Estradiol 3-benzoate Phase 4
20 Estradiol valerate Phase 4 979-32-8
21 Estrogens Phase 4
22 Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
23 Hormones Phase 4,Phase 3,Phase 2,Early Phase 1
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
25 insulin Phase 4
26 Insulin, Globin Zinc Phase 4
27 Mitogens Phase 4
28 Neurotransmitter Agents Phase 4,Phase 2,Phase 3
29 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
30 Polyestradiol phosphate Phase 4
31 Sympatholytics Phase 4
32 Adjuvants, Immunologic Phase 4
33 Anti-Infective Agents Phase 4,Phase 3,Phase 2
34 Antiviral Agents Phase 4,Phase 3,Phase 2
35 Interferon-beta Phase 4
36 interferons Phase 4,Phase 3,Phase 2
37 Hypoglycemic Agents Phase 4,Phase 3
38 Antidepressive Agents Phase 4,Phase 2,Phase 3,Phase 1
39 Antidepressive Agents, Second-Generation Phase 4
40 Antiparkinson Agents Phase 4
41 Cholinergic Agents Phase 4,Phase 2,Phase 3
42 Cholinergic Antagonists Phase 4
43 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
44 Cytochrome P-450 Enzyme Inhibitors Phase 4
45 Dopamine Agents Phase 4
46 Dopamine Uptake Inhibitors Phase 4
47 Muscarinic Antagonists Phase 4
48 Neurotransmitter Uptake Inhibitors Phase 4
49 Parasympatholytics Phase 4
50 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 149)

# Name Status NCT ID Phase Drugs
1 Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT) Unknown status NCT01052623 Phase 4 Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
2 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
3 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Completed NCT02733679 Phase 4 Metformin;Pioglitazone
4 An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia Completed NCT01716221 Phase 4 bupropion & Citalopram;Bupropion & Placebo;Placebo & Citalopram;Placebo & Placebo
5 Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
6 A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970137 Phase 3 KPS-0373, High dose;KPS-0373, Low dose
7 A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970124 Phase 3 KPS-0373, High dose;KPS-0373, Low dose
8 An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970111 Phase 3 KPS-0373, High dose;KPS-0373, Low dose
9 A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970098 Phase 3 KPS-0373, High dose;KPS-0373, Low dose;Placebo
10 Safety, Tolerability and Efficacy of ACTIMMUNE Dose Escalation in Friedreich's Ataxia Study Completed NCT02593773 Phase 3 Interferon γ-1b
11 Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Completed NCT02415127 Phase 3 Interferon γ-1b;Placebo
12 STEADFAST Long-Term Safety Extension Completed NCT02797080 Phase 3 interferon γ-1b
13 Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10 Completed NCT02333305 Phase 3
14 Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI) Completed NCT01303406 Phase 3 Idebenone;Placebo
15 Efficacy of Riluzole in Hereditary Cerebellar Ataxia Completed NCT01104649 Phase 2, Phase 3 riluzole;Placebo comparator
16 Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3 Completed NCT01096082 Phase 2, Phase 3 Lithium Carbonate;Placebo
17 Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension) Completed NCT00993967 Phase 3 idebenone
18 A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients Completed NCT00905268 Phase 3 idebenone;Placebo
19 Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept Completed NCT00811681 Phase 3 pioglitazone;Placebo
20 Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients Completed NCT00697073 Phase 3 Idebenone
21 Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT) Completed NCT00656409 Phase 3 Conjugated pneumococcal vaccine (Prevenar)
22 Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Completed NCT00537680 Phase 3 Idebenone;Idebenone;Placebo
23 EDS in Ataxia Telangiectasia Patients Recruiting NCT02770807 Phase 3 EDS-EP dose range of ~5-10 mg DSP/infusion;EDS-EP dose range of ~14-22 mg DSP/infusion;Placebo
24 An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Active, not recruiting NCT02889302 Phase 3 KPS-0373;Placebo
25 An Open Pilot Trial of BHV-4157 Active, not recruiting NCT03408080 Phase 3 BHV-4157
26 Trial in Adult Subjects With Spinocerebellar Ataxia Active, not recruiting NCT02960893 Phase 2, Phase 3 BHV-4157;Placebo Comparator
27 Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL) Not yet recruiting NCT03347344 Phase 3 Riluzole;Placebo
28 Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia Terminated NCT00803868 Phase 2, Phase 3 varenicline;placebo
29 Clinical Study to Evaluate the Safety and Efficacy BMMNC in Cerebellar Ataxia Unknown status NCT01958177 Phase 1, Phase 2
30 4-Aminopyridine in Episodic Ataxia Type 2 Unknown status NCT01543750 Phase 2 4-Aminopyridine;Placebo
31 A New Method to Treat Hereditary Cerebellar Ataxia - Umbilical Cord Mesenchymal Stem Cells Transplantation Unknown status NCT01489267 Phase 2
32 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia Unknown status NCT01360164 Phase 1, Phase 2
33 Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia Completed NCT00202397 Phase 2 Riluzole
34 A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01384435 Phase 2 KPS-0373;KPS-0373;KPS-0373;KPS-0373;Placebo
35 Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease Completed NCT02147886 Phase 2 Cabaletta for IV infusion once weekly during 24 weeks;Cabaletta for IV infusion once weekly during 24 weeks
36 A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01004016 Phase 2 KPS-0373;Placebo
37 Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT00863538 Phase 2 KPS-0373
38 The Influence of Deep TMS on Cerebellar Signs in Patients With Machado Joseph Disease Completed NCT02039206 Phase 2
39 High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration Completed NCT00034242 Phase 2 high-dose intravenous immunoglobulin (IVIG)
40 A First in Human Study of RT001 in Patients With Friedreich's Ataxia Completed NCT02445794 Phase 1, Phase 2 RT001;RT001 comparator
41 A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients Completed NCT02035020 Phase 2 gamma interferon
42 Interferon Gamma-1b in Friedreich Ataxia (FRDA) Completed NCT01965327 Phase 2 Interferon Gamma-1b
43 EPI-743 in Friedreich's Ataxia Point Mutations Completed NCT01962363 Phase 2 EPI-743
44 Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia Completed NCT01728064 Phase 2 Placebo;EPI-743 400 mg;EPI-743 200 mg
45 Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells Completed NCT01649687 Phase 1, Phase 2
46 Efficacy Study of Epoetin Alfa in Friedreich Ataxia Completed NCT01493973 Phase 2 Epoetin alfa;Placebo
47 Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia Completed NCT01350440 Phase 2
48 A Study of Resveratrol as Treatment for Friedreich Ataxia Completed NCT01339884 Phase 1, Phase 2 Resveratrol
49 Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia Completed NCT01035671 Phase 2 alpha-tocopherolquinone (A0001);alpha-tocopherolquinone (A0001);placebo
50 Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia Completed NCT01016366 Phase 2 Lu AA24493;Placebo

Search NIH Clinical Center for Cerebellar Disease

Cochrane evidence based reviews: cerebellar diseases

Genetic Tests for Cerebellar Disease

Anatomical Context for Cerebellar Disease

MalaCards organs/tissues related to Cerebellar Disease:

38
Cerebellum, Brain, Liver, Eye, Testes, Spinal Cord, Cortex

Publications for Cerebellar Disease

Articles related to Cerebellar Disease:

(show top 50) (show all 93)
# Title Authors Year
1
Antibodies to inositol 1,4,5-triphosphate receptor 1 in patients with cerebellar disease. ( 27957507 )
2017
2
Cerebellar Disease Mimicking Cerebrotendinous Xanthomatosis: Langerhans Cell Histiocytosis. ( 28554492 )
2017
3
Internally Versus Externally Cued Speech in Parkinson's Disease and Cerebellar Disease. ( 28654941 )
2017
4
Cerebellar disease associated with anti-glutamic acid decarboxylase antibodies: review. ( 28689294 )
2017
5
Cerebellar Disease of Ruminants. ( 28166936 )
2017
6
A toolbox to visually explore cerebellar shape changes in cerebellar disease and dysfunction. ( 28479655 )
2016
7
The effect of a task-specific locomotor training strategy on gait stability in patients with cerebellar disease: a feasibility study. ( 27216372 )
2016
8
Cerebrospinal Fluid Calbindin D Concentration as a Biomarker of Cerebellar Disease Progression in Niemann-Pick Type C1 Disease. ( 27307499 )
2016
9
Using human induced pluripotent stem cells to model cerebellar disease: Hope and hype. ( 25985846 )
2015
10
Assessment of postural stability in patients with cerebellar disease using gyroscope data. ( 26118512 )
2015
11
Automated cerebellar lobule segmentation with application to cerebellar structural analysis in cerebellar disease. ( 26408861 )
2015
12
Acquired Esotropia in Cerebellar Disease: A Case Series Illustrating Misdiagnosis as Isolated Lateral Rectus Paresis and Progression Over Time. ( 27928333 )
2015
13
Neuro-ophthalmic manifestations of cerebellar disease. ( 25439294 )
2014
14
Torpedo formation and Purkinje cell loss: modeling their relationship in cerebellar disease. ( 24590661 )
2014
15
Training balance with opto-kinetic stimuli in the home: a randomized controlled feasibility study in people with pure cerebellar disease. ( 25082955 )
2014
16
Clinical manifestations of cerebellar disease. ( 25439285 )
2014
17
Effects of balance and gait rehabilitation in cerebellar disease of vascular or degenerative origin. ( 24398721 )
2014
18
Effects of task constraints on obstacle avoidance strategies in patients with cerebellar disease. ( 23022155 )
2013
19
Disturbed vestibular-neck interaction in cerebellar disease. ( 23081756 )
2013
20
Dichotic listening test in patients with chronic cerebellar disease. ( 22133971 )
2012
21
Cerebellar ataxia rehabilitation trial in degenerative cerebellar diseases. ( 22140200 )
2012
22
Balance rehabilitation therapy by tongue electrotactile biofeedback in patients with degenerative cerebellar disease. ( 23232167 )
2012
23
Effects of cerebellar disease on sequences of rapid eye movements. ( 21385592 )
2011
24
Vestibulo-cerebellar disease impairs the central representation of self-orientation. ( 21431098 )
2011
25
68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease. ( 21157217 )
2011
26
Spike removal through multiscale wavelet and entropy analysis of ocular motor noise: a case study in patients with cerebellar disease. ( 21262262 )
2011
27
Spinocerebellar ataxia type 7 cerebellar disease requires the coordinated action of mutant ataxin-7 in neurons and glia, and displays non-cell-autonomous bergmann glia degeneration. ( 22072678 )
2011
28
Aphasia and neglect are uncommon in cerebellar disease: negative findings in a prospective study in acute cerebellar stroke. ( 20680538 )
2010
29
Longitudinal tracking of gait and balance impairments in cerebellar disease. ( 20544808 )
2010
30
Long-term effects of coordinative training in degenerative cerebellar disease. ( 20737551 )
2010
31
Intensive coordinative training improves motor performance in degenerative cerebellar disease. ( 19864636 )
2009
32
Clinical manifestation of focal cerebellar disease as related to the organization of neural pathways. ( 18439215 )
2008
33
Time estimation in Parkinson's disease and degenerative cerebellar disease. ( 18580578 )
2008
34
Reduced saccadic resilience and impaired saccadic adaptation due to cerebellar disease. ( 18184318 )
2008
35
The Croonian Lectures On The Clinical Symptoms Of Cerebellar Disease And Their Interpretation. Lecture I. 1922. ( 17510914 )
2007
36
Clinical symptoms of cerebellar disease and their interpretation. ( 18041661 )
2007
37
Pediatric periodic alternating gaze deviation with midline cerebellar disease. ( 17280848 )
2007
38
Commentary on 'Holmes G. Clinical symptoms of cerebellar disease and their interpretation. Lecture I. The Lancet 1922;202 (Vol. 1 for 1922):1178-1182, and Holmes G. Clinical symptoms of cerebellar disease and their interpretation. Lecture II. The Lancet 1922;202 (Vol. 1 for 1922):1232-1237'. ( 17566248 )
2007
39
The Croonian Lectures on the clinical symptoms of cerebellar disease and their interpretation. Lecture II. 1922. ( 17566247 )
2007
40
Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. ( 17404205 )
2007
41
Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. ( 17000981 )
2006
42
Studies of eccentric gaze stability: effects of pitch head position on horizontal gaze-holding in patients with cerebellar disease. ( 15827030 )
2005
43
Asymmetry of the pitch vestibulo-ocular reflex in patients with cerebellar disease. ( 15826988 )
2005
44
Cerebellar disease alters the axis of the high-acceleration vestibuloocular reflex. ( 16033941 )
2005
45
Diagnostic approach to cerebellar disease in children. ( 16417854 )
2005
46
Cerebellar disease and disease characterized by dysmetria or tremors. ( 15203226 )
2004
47
Dissociation of habit-learning in Parkinson's and cerebellar disease. ( 11970808 )
2002
48
Single-neuron analysis of human thalamus in patients with intention tremor and other clinical signs of cerebellar disease. ( 11929926 )
2002
49
Cerebellar-subcortical circuits and mania in cerebellar disease. ( 11207338 )
2001
50
Directional abnormalities of vestibular and optokinetic responses in cerebellar disease. ( 10372073 )
1999

Variations for Cerebellar Disease

Expression for Cerebellar Disease

Search GEO for disease gene expression data for Cerebellar Disease.

Pathways for Cerebellar Disease

GO Terms for Cerebellar Disease

Cellular components related to Cerebellar Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.65 ATXN10 CACNA1A CALB1 PRKCG SACS
2 axon GO:0030424 9.62 ATP1A3 CALB1 SACS SETX
3 neuronal cell body GO:0043025 9.55 ATP1A3 ATXN10 CACNA1A CALB1 SPTBN2
4 cytoplasm GO:0005737 9.53 APTX ATM ATP1A3 ATXN10 ATXN3 ATXN7
5 nucleolus GO:0005730 9.5 APTX ATM ATXN3 ATXN7 ITPR1 NOP56

Biological processes related to Cerebellar Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion transmembrane transport GO:0034220 9.26 ATP1A3 ATP2B3 CACNA1A ITPR1
2 response to pain GO:0048265 9.16 CACNA1A PRKCG
3 regulation of cardiac conduction GO:1903779 8.8 ATP1A3 ATP2B3 ITPR1

Molecular functions related to Cerebellar Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium ion transmembrane transporter activity GO:0015085 8.62 ATP2B3 ITPR1

Sources for Cerebellar Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....